Act1 drives chemoresistance via regulation of antioxidant RNA metabolism and redox homeostasis
Journal of Experimental Medicine · 2024
DOI: 10.1084/jem.20231442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2024. Verfasst von Lingzi Hong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Antioxidants, Drug Resistance, Neoplasm, Homeostasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Case Western Reserve University.
Abstract (Originalsprache)
The IL-17 receptor adaptor molecule Act1, an RNA-binding protein, plays a critical role in IL-17–mediated cancer progression. Here, we report a novel mechanism of how IL-17/Act1 induces chemoresistance by modulating redox homeostasis through epitranscriptomic regulation of antioxidant RNA metabolism. Transcriptome-wide mapping of direct Act1–RNA interactions revealed that Act1 binds to the 5′UTR of antioxidant mRNAs and Wilms’ tumor 1–associating protein (WTAP), a key regulator in m6A methyltransferase complex. Strikingly, Act1’s binding sites are located in proximity to m6A modification sites, which allows Act1 to promote the recruitment of elF3G for cap-independent translation. Loss of Act1’s RNA binding activity or Wtap knockdown abolished IL-17–induced m6A modification and translation of Wtap and antioxidant mRNAs, indicating a feedforward mechanism of the Act1–WTAP loop. We then developed antisense oligonucleotides (Wtap ASO) that specifically disrupt Act1’s binding to Wtap mRNA, abolishing IL-17/Act1-WTAP-mediated antioxidant protein production during chemotherapy. Wtap ASO substantially increased the antitumor efficacy of cisplatin, demonstrating a potential therapeutic strategy for chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
- Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
- Center for RNA Science and Therapeutics, School of Medicine, Case Western Reserve University , Cleveland, OH, USA.
- Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
- Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
- Takeda Pharmaceutical Company , San Diego, CA, USA.
ORCID-Profile: Lingzi Hong, Tomasz Herjan, Xing Chen, Leah L Zagore, Katarzyna Bulek, Han Wang, Chi-Fu Jeffrey Yang, Donny D Licatalosi, Xiaoxia Li, Xiao Li
Förderung
- NIH HHS
- NCI NIH HHS
- Case Western Reserve University
- National Institutes of Health
Zitieren
APA
Hong, L., Herjan, T., Chen, X., Zagore, L. L., Bulek, K., Wang, H., Yang, C. J., Licatalosi, D. D., Li, X., & Li, X. (2024). Act1 drives chemoresistance via regulation of antioxidant RNA metabolism and redox homeostasis. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20231442
Vancouver
Hong L, Herjan T, Chen X, Zagore LL, Bulek K, Wang H, et al. Act1 drives chemoresistance via regulation of antioxidant RNA metabolism and redox homeostasis. Journal of Experimental Medicine. 2024. doi:10.1084/jem.20231442
BibTeX
@article{Hong2024,
author = {Hong, Lingzi and Herjan, Tomasz and Chen, Xing and Zagore, Leah L and Bulek, Katarzyna and Wang, Han and Yang, Chi-Fu Jeffrey and Licatalosi, Donny D and Li, Xiaoxia and Li, Xiao},
title = {Act1 drives chemoresistance via regulation of antioxidant RNA metabolism and redox homeostasis},
journal = {Journal of Experimental Medicine},
year = {2024},
doi = {10.1084/jem.20231442}
}
EUVIMED